Predicting toxicity during 5-fluorocytosine (5-FC) therapy by plasma level monitoring: a lesson to learn from cytostatic 5-fluorouracil (5 FU) pro-drugs.
Guentert
T W
TW
F. Hoffmann-La Roche & Co. Limited Company, Basle, Switzerland.
D000963:Antimetabolites / Q000097:blood / Q000633:toxicity*; D005467:Floxuridine / Q000493:pharmacokinetics; D005437:Flucytosine / Q000097:blood / Q000493:pharmacokinetics / Q000633:toxicity*; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008657:Metabolic Clearance Rate; D008991:Monitoring, Physiologic / Q000379:methods; D011355:Prodrugs
D000963:Antimetabolites; D011355:Prodrugs; D005467:Floxuridine; D005437:Flucytosine; D005472:Fluorouracil